LT3405582T - Patobulinta vakciną nuo maliarijos adenoviruso, koduojančio ir eksponuojančio maliarijos antigeną, pagrindu - Google Patents

Patobulinta vakciną nuo maliarijos adenoviruso, koduojančio ir eksponuojančio maliarijos antigeną, pagrindu

Info

Publication number
LT3405582T
LT3405582T LTEP17701449.5T LT17701449T LT3405582T LT 3405582 T LT3405582 T LT 3405582T LT 17701449 T LT17701449 T LT 17701449T LT 3405582 T LT3405582 T LT 3405582T
Authority
LT
Lithuania
Prior art keywords
malaria
displaying
vaccine encoding
adenovirus based
antigen
Prior art date
Application number
LTEP17701449.5T
Other languages
English (en)
Inventor
Jerôme CUSTERS
Jort Vellinga
Marija VUJADINOVIC
Esmeralda VAN DER HELM
Original Assignee
Janssen Vaccines & Prevention B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention B.V. filed Critical Janssen Vaccines & Prevention B.V.
Publication of LT3405582T publication Critical patent/LT3405582T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/015Hemosporidia antigens, e.g. Plasmodium antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445Plasmodium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10342Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP17701449.5T 2016-01-21 2017-01-19 Patobulinta vakciną nuo maliarijos adenoviruso, koduojančio ir eksponuojančio maliarijos antigeną, pagrindu LT3405582T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16152163 2016-01-21
PCT/EP2017/051029 WO2017125463A1 (en) 2016-01-21 2017-01-19 An improved adenovirus based malaria vaccine encoding and displaying a malaria antigen

Publications (1)

Publication Number Publication Date
LT3405582T true LT3405582T (lt) 2020-12-10

Family

ID=55398173

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17701449.5T LT3405582T (lt) 2016-01-21 2017-01-19 Patobulinta vakciną nuo maliarijos adenoviruso, koduojančio ir eksponuojančio maliarijos antigeną, pagrindu

Country Status (9)

Country Link
US (1) US10517938B2 (lt)
EP (1) EP3405582B1 (lt)
JP (1) JP6934877B2 (lt)
DK (1) DK3405582T3 (lt)
HR (1) HRP20201371T1 (lt)
HU (1) HUE050987T2 (lt)
LT (1) LT3405582T (lt)
SI (1) SI3405582T1 (lt)
WO (1) WO2017125463A1 (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023812A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children VACCINE COMPOSITION AGAINST MALARIA AND METHOD THEREOF
EP3820997A4 (en) * 2018-07-09 2022-09-21 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College MALARIA VIRAL VACCINE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ539813A (en) * 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
US20100272753A1 (en) * 2006-10-26 2010-10-28 The Johns Hopkins University Recombinant Adenovirus Vaccines
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
WO2011022002A1 (en) 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
WO2012023995A1 (en) 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes

Also Published As

Publication number Publication date
SI3405582T1 (sl) 2020-10-30
JP6934877B2 (ja) 2021-09-15
US10517938B2 (en) 2019-12-31
WO2017125463A1 (en) 2017-07-27
JP2019508031A (ja) 2019-03-28
EP3405582A1 (en) 2018-11-28
EP3405582B1 (en) 2020-08-12
DK3405582T3 (da) 2020-11-02
US20190083597A1 (en) 2019-03-21
HUE050987T2 (hu) 2021-01-28
HRP20201371T1 (hr) 2020-11-27

Similar Documents

Publication Publication Date Title
GB2523740B (en) Image encoding and display
GB2523555B (en) Image encoding and display
ZA201805547B (en) Novel antigen for use in malaria vaccine
EP3200831A4 (en) Vaccines having an antigen and interleukin-21 as an adjuvant
HK1254806A1 (zh) 包含一種或多種群體表位基共序列抗原的hiv疫苗
EP3385286A4 (en) ANTIGEN VACCINE WITH INCREASED IMMUNOGENICITY
IL266237A (en) Tolerogenic DNA composition
IL252644A0 (en) Vaccines based on jaundice core antigens b
IL287985A (en) A peptide derived from koc1 and a component containing it
GB201616904D0 (en) Vaccine
HK1248536A1 (zh) 疫苗組合物及其用途
LT3405582T (lt) Patobulinta vakciną nuo maliarijos adenoviruso, koduojančio ir eksponuojančio maliarijos antigeną, pagrindu
IL247295A0 (en) Components based on antigens with a yellow core b
IL254648A0 (en) Vaccines based on hepatitis b core antigens
GB201608821D0 (en) Vaccines
GB201615427D0 (en) Francisella glycoconjugate vaccines
GB201718337D0 (en) Malaria vaccine
GB201712092D0 (en) Malaria vaccine
PT3297666T (pt) Adjuvante e vacina molecular
GB201712904D0 (en) Vaccine
PT3534936T (pt) Vacina de adn tolerogénica
GB201704126D0 (en) Vaccine
GB201703809D0 (en) Vaccine
GB201704892D0 (en) Improved vaccines
GB201706798D0 (en) Vaccination